Arrowhead Pharmaceuticals Inc. is a Arrowhead Pharmaceuticals Inc is an American biotechnology company.
Arrowhead Pharmaceuticals Inc. (ARWR) had a rough trading day for Tuesday November 24 as shares tumbled 11.45%, or a loss of $-7.81 per share, to close at $60.39. After opening the day at $65.50, shares of Arrowhead Pharmaceuticals Inc. traded as high as $66.75 and as low as $58.02. Volume was 3.52 million shares over 37,190 trades, against an average daily volume of n/a shares and a total float of 102.29 million.
As a result of the decline, Arrowhead Pharmaceuticals Inc. now has a market cap of $6.18 billion. In the last year, shares of Arrowhead Pharmaceuticals Inc. have traded between a range of $73.73 and $19.52, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Arrowhead Pharmaceuticals Inc. is based out of Pasadena, CA and has some 109 employees. Its CEO is Christopher Anzalone.